16,565 Shares in Puma Biotechnology, Inc. (NASDAQ:PBYI) Bought by Victory Capital Management Inc.

Victory Capital Management Inc. purchased a new stake in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 16,565 shares of the biopharmaceutical company’s stock, valued at approximately $54,000.

Other large investors have also recently bought and sold shares of the company. Great Point Partners LLC bought a new stake in shares of Puma Biotechnology during the 4th quarter valued at about $4,734,000. Bank of New York Mellon Corp boosted its holdings in shares of Puma Biotechnology by 63.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 308,997 shares of the biopharmaceutical company’s stock worth $1,007,000 after buying an additional 120,104 shares in the last quarter. Panagora Asset Management Inc. bought a new stake in shares of Puma Biotechnology in the 2nd quarter valued at $335,000. Assenagon Asset Management S.A. lifted its position in shares of Puma Biotechnology by 99.9% during the 2nd quarter. Assenagon Asset Management S.A. now owns 140,205 shares of the biopharmaceutical company’s stock valued at $457,000 after acquiring an additional 70,060 shares during the period. Finally, EntryPoint Capital LLC bought a new position in Puma Biotechnology during the first quarter worth $329,000. 61.29% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

PBYI has been the topic of several research reports. HC Wainwright reiterated a “buy” rating and set a $7.00 price objective on shares of Puma Biotechnology in a report on Friday, August 2nd. StockNews.com lowered Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 13th.

Insider Activity

In related news, CEO Alan H. Auerbach sold 21,920 shares of the company’s stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $3.70, for a total transaction of $81,104.00. Following the completion of the sale, the chief executive officer now owns 7,063,515 shares in the company, valued at $26,135,005.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Puma Biotechnology news, Director Michael Patrick Miller sold 23,358 shares of Puma Biotechnology stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $3.49, for a total transaction of $81,519.42. Following the transaction, the director now owns 47,000 shares of the company’s stock, valued at approximately $164,030. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Alan H. Auerbach sold 21,920 shares of the business’s stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $3.70, for a total value of $81,104.00. Following the completion of the transaction, the chief executive officer now owns 7,063,515 shares in the company, valued at approximately $26,135,005.50. The disclosure for this sale can be found here. Insiders have sold 82,263 shares of company stock worth $286,469 over the last 90 days. 23.70% of the stock is currently owned by corporate insiders.

Puma Biotechnology Stock Performance

Shares of PBYI stock opened at $2.55 on Wednesday. The company has a current ratio of 1.32, a quick ratio of 1.23 and a debt-to-equity ratio of 0.90. The firm has a fifty day simple moving average of $3.00 and a two-hundred day simple moving average of $3.88. Puma Biotechnology, Inc. has a 12 month low of $2.13 and a 12 month high of $7.73. The firm has a market capitalization of $123.01 million, a PE ratio of 7.73 and a beta of 1.09.

Puma Biotechnology (NASDAQ:PBYI) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01. The company had revenue of $47.10 million for the quarter, compared to analyst estimates of $43.99 million. Puma Biotechnology had a net margin of 4.01% and a return on equity of 18.36%. During the same quarter in the prior year, the business posted $0.05 EPS. Analysts forecast that Puma Biotechnology, Inc. will post 0.25 EPS for the current fiscal year.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.